PAHC
Phibro Animal Health Corporation Class A
PHARMACEUTICAL PREPARATIONS
Best Pharmaceutical Stocks 2026 →
Phibro Animal Health (PAHC) Stock: Buy, Sell, or Hold?
$35.15
+0.51 (+1.47%)
▲
5d:
-10.85%
30d:
-4.51%
90d:
+3.2%
Open in Live Scanner
70/30 Portfolio Builder
Earnings: Nov 04, 2026
0d
Protect PAHC Gains
Updated Nov 11, 12:00 AM ET
QUANTITATIVE VERDICT
WAIT
LOW Confidence (92%)
Quality Score
61/100
Position
OVERSOLD
30-Day Fair Range
$35.96 – $39.31
Position: OVERSOLD
Forward P/E & Valuation
10.5x
CHEAP
vs 12.9x historical avg
Wall Street Target
$47.00
+33.7% upside
Options IV & Volume
23th pct IV
HIGH volume confirmation
Support / Resistance
$32.91 / $40.54
Trend: Uptrend
Executive Thesis & Bottom Line
Forward Earnings Fair Value & Price Prediction →
⏸️ WAIT FOR STABILIZATION: PAHC is down 10.9% over the last 5 days. While fundamentals may be solid, catching a falling knife is risky. Wait for price to stabilize before entering.
Get Alerted When PAHC Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$58.92
Based on 6.5% avg growth
INTRINSIC VALUE TODAY
$36.59
3.9% Margin of Safety
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 12.9x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: PAHC is currently trading at $35.15, which is considered oversold relative to its 30-day fair value range of $35.96 to $39.31. From a valuation perspective, the stock is trading at a discount (Forward PE: 10.5) compared to its historical average (12.9). Remarkably, the market is currently pricing in an annual earnings decline of 6.6% over the next few years. This pessimistic expectation contrasts with the company's recent 10.8% earnings growth, suggesting potential undervaluation if the company simply maintains stability.
Technical Outlook: Technically, PAHC is in a uptrend. Immediate support is located at $32.91, while resistance sits at $40.54.
Market Sentiment: PAHC scores 62/100 on our bottoming-setup gauge — the chart has corrected and is stabilizing (RSI reset, momentum turning up), historically a favorable entry zone. In the options market, Implied Volatility is low (23th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $47.00 (+33.7%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, PAHC is in a uptrend. Immediate support is located at $32.91, while resistance sits at $40.54.
Market Sentiment: PAHC scores 62/100 on our bottoming-setup gauge — the chart has corrected and is stabilizing (RSI reset, momentum turning up), historically a favorable entry zone. In the options market, Implied Volatility is low (23th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $47.00 (+33.7%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
OVERSOLD
Historical Trading Range
$35.96 -
$39.31
Company Quality Score
61/100
(BUY)
Options IV Signal
23th percentile
(COMPLACENCY WARNING)
Volume Confirmation
HIGH
Confidence Score
92.3%
Trading Range & Key Levels
30-Day Trading Range
$35.96 -
$39.31
Current vs Trading Range
OVERSOLD
Expected Move (7 Days)
±$2.53
(7.2%)
Support Level
$32.91
Resistance Level
$40.54
Current Trend
Uptrend
Technical data as of
Nov 11, 2026
Protect Your Profits
Holding PAHC? Use our AI-powered strategies to protect your downside while keeping your long-term position.
View Profit Protection PlanQuantitative Signal Breakdown
- BULLISH: Price oversold vs 30-day range
- BULLISH: Options cheap (IV 23th percentile)
- BULLISH: Strong technical setup (62/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 33.7% below Wall St target ($47.00)
- BULLISH: Bottoming setup score 62/100 — corrected, stabilizing, and turning up
- WARNING: Recommendation downgraded due to -10.9% 5-day decline - wait for stabilization
Fundamental Context
Forward P/E (Next Year Est.)
10.51
Wall Street Target
$47.00
(+33.7%)
Revenue Growth (YoY)
6.3%
Earnings Growth (YoY)
10.8%
Profit Margin
6.7%
Valuation Discount vs History
-6.6% cheaper
PE vs Historical
10.5 vs 12.9
CHEAP
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
-6.6%
(market-implied from PE analysis)
1-Year Target
$32.83
(-7%)
2-Year Target
$30.66
(-13%)
3-Year Target
$28.64
(-19%)
3-Yr Target (if PE normalizes)
(PE: 11→13)
$35.15
(0%)
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 19.9, Growth: 8.9%)
$85.65
(+144%)
Base:
(SPY PE: 10.5, Growth: 8.9%)
$45.33
(+29%)
Bear:
(PE: 8.9, Growth: 8.9%)
$38.53
(+10%)
📈
Valuation based on Current Earnings
RECOVERY PLAY: Stock looks expensive now (14x PE), but valuation improves significantly next year (11x PE) as earnings recover.
Trailing PE: 13.80 | Current EPS (TTM): $2.51
Bull Case
$50.76
(+44%)
Analyst growth 33.2%, PE expands to 15.2
Base Case
$46.15
(+31%)
Market implied 33.2%, PE stable at 13.8
Bear Case
$23.56
(-33%)
Severe decline -20.0%, PE contracts to 11.7
These are projections based on PE multiples and EPS growth scenarios, not predictions. Actual results may vary significantly.
💡
Upside Surprise Potential
If earnings stabilize (0% growth), PE could expand from 10.5 to 12.9
Stabilization Target:
$43.14
(+22.7%)
PE Expansion Potential:
+22.7%
Share PAHC Analysis
Share this live PAHC analysis (with rich preview card) to Reddit, StockTwits, X, or embed the chart on your blog.
bloggers & journalists: you are free to use our charts with attribution.Reddit & Retail Trader Sentiment (PAHC)
Bullish
2 Retail Mentions
Reddit / WSB Comments
1
Bullish
StockTwits Volume
1 msgs
24h retail stream
Last Tracked
Aug 7, 2026
Daily AI digest
AI Retail Discussion Summary:
A financial analysis of $PAHC reveals a bullish sentiment on StockTwits, with investors seeing potential in the stock's current undervalued state as indicated by a Zacks Rank #2 (Buy) and a Value grade of A. The latest news article suggests that value investors may find $PAHC attractive due to its low P/E ratio and PEG ratio, as well as its P/S ratio being lower than the industry average.
Key Retail Themes:
Undervalued stock
Value investing strategy
Aggregated from r/wallstreetbets, r/stocks & StockTwits streams.
View All Trending Reddit & WSB Stocks →
Last updated: November 11, 2026 7:44 PM ET
Data refreshes hourly during market hours. Next update: 8:44 PM
Data refreshes hourly during market hours. Next update: 8:44 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is PAHC showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Drug Manufacturers - Specialty & Generic Stocks
Top-rated stocks in Drug Manufacturers - Specialty & Generic by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
NBIX
Neurocrine Biosciences I… |
STRONG BUY
29 analysts |
$208 | 23 SELL |
|
ALKS
Alkermes Plc |
STRONG BUY
20 analysts |
$58 | 33 SELL |
|
AQST
Aquestive Therapeutics I… |
STRONG BUY
9 analysts |
$9 | 62 BUY |
|
UTHR
United Therapeutics Corp… |
STRONG BUY
15 analysts |
$687 | 52 HOLD |
|
HROW
Harrow Health Inc |
STRONG BUY
9 analysts |
$63 | 53 HOLD |
Advanced PAHC Option Strategies
Professional options setups generated by AI based on today's PAHC price and gamma walls.
Explore More Analysis & Live Quant Tools
Part A: Deep-Dive PAHC Research Pages
